Testing

Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive, accurate and actionable results. Identifying a genetic cause helps guide the complex decisions involved with treating kidney disease.

By Barbara J. Toman • August 30, 2022

Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide treatment decisions. Often misdiagnosed, CIDP is treatable if detected early.

By Barbara J. Toman • August 23, 2022

John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to cause membranous nephropathy — a condition that can lead to kidney failure.

By Barbara J. Toman • August 16, 2022

Rong He, M.D., describes how Mayo Clinic Laboratories’ NPM1Q assay detects all known forms of a genetic mutation found in about 30% of people with acute myeloid leukemia, or AML. Identifying the NPM1 mutation is critical for clinical decision-making.

By Barbara J. Toman • August 9, 2022

In July 2022, Mayo Clinic Laboratories announced fifteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Samantha Rossi • August 4, 2022

Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the diagnosis of heparin induced thrombocytopenia, or HIT, which can have devastating consequences for patients.

By Barbara J. Toman • August 2, 2022

This page includes updates posted to mayocliniclabs.com during the month of July.

By Michael Hutchison • August 2, 2022

Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for managing clinical care.

By Barbara J. Toman • July 26, 2022

In June 2022, Mayo Clinic Laboratories announced forty-nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Meghann Southwick • July 7, 2022

This list includes updates posted to mayocliniclabs.com during the month of June.

By Michael Hutchison • July 2, 2022

The Department of Health and Human Services has named Mayo Clinic Laboratories as one of five commercial laboratories to expand access and capacity for monkeypox testing.

By Suzanne Ferguson • June 23, 2022

Cherisse Marcou, Ph.D., and Marissa Ellingson, M.S., CGC, discuss whole exome sequencing (WES) at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, and copy number variants on approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited illness.

By Barbara J. Toman • June 14, 2022

In May 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Meghann Southwick • June 2, 2022